Equity Overview
Price & Market Data
Price: $4.28
Daily Change: -$0.24 / 5.61%
Daily Range: $4.20 - $4.69
Market Cap: $21,665,670
Daily Volume: 121,016
Performance Metrics
1 Week: -18.73%
1 Month: -7.06%
3 Months: 6.85%
6 Months: -10.99%
1 Year: 18.93%
YTD: -14.60%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.